Insigneo Advisory Services LLC Increases Holdings in Becton, Dickinson and Company (NYSE:BDX)

Insigneo Advisory Services LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 19.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,760 shares of the medical instruments supplier’s stock after buying an additional 608 shares during the quarter. Insigneo Advisory Services LLC’s holdings in Becton, Dickinson and Company were worth $861,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of BDX. Brighton Jones LLC boosted its position in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 877 shares during the last quarter. Foster Victor Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company during the first quarter worth about $6,406,000. Van ECK Associates Corp boosted its holdings in Becton, Dickinson and Company by 3.1% in the 4th quarter. Van ECK Associates Corp now owns 14,738 shares of the medical instruments supplier’s stock valued at $3,344,000 after purchasing an additional 450 shares during the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $21,607,000. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Becton, Dickinson and Company by 56.5% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 45,792 shares of the medical instruments supplier’s stock valued at $10,371,000 after buying an additional 16,537 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 479 shares of the firm’s stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $197.28, for a total value of $94,497.12. Following the sale, the executive vice president now owns 4,887 shares of the company’s stock, valued at $964,107.36. This trade represents a 8.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Shan sold 1,166 shares of the business’s stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president now owns 4,575 shares of the company’s stock, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The disclosure for this sale can be found here. 0.36% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BDX shares. Raymond James Financial lowered shares of Becton, Dickinson and Company from an “outperform” rating to a “market perform” rating in a research report on Friday, May 2nd. Morgan Stanley reduced their target price on Becton, Dickinson and Company from $280.00 to $196.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 6th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Friday, May 2nd. Bank of America downgraded Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $190.00 price objective for the company. in a research report on Thursday, May 1st. Finally, The Goldman Sachs Group cut shares of Becton, Dickinson and Company from a “buy” rating to a “neutral” rating and set a $192.00 target price on the stock. in a research report on Friday, May 2nd. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $219.22.

Becton, Dickinson and Company Price Performance

BDX stock opened at $170.01 on Wednesday. The business’s fifty day moving average price is $181.67 and its 200 day moving average price is $212.31. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. The company has a market capitalization of $48.73 billion, a PE ratio of 32.45, a P/E/G ratio of 1.30 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $3.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.28 by $0.07. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.35 billion. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.17 earnings per share. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 30th. Investors of record on Monday, June 9th will be paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.45%. The ex-dividend date of this dividend is Monday, June 9th. Becton, Dickinson and Company’s payout ratio is currently 79.39%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.